Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01056315 · ClinicalTrials.gov registry record · Phase 2
A Trial in Painful Diabetic Peripheral Neuropathy With GRT3983Y
A Phase 2 study, sponsored by Grünenthal.
- Terminated
- Registry status
- Phase 2
- Development phase
- 553
- Enrollment target
NCT01056315: Clinical Trial Phase 2 study, sponsored by Grünenthal.
NCT01056315 is a Phase 2 study that was terminated before completion, run by Grünenthal. The registered enrollment target is 553 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (316% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01056315, a Phase 2 study, was terminated before completion, sponsored by Grünenthal.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 553 participants
- Enrollment target
Study Summary
This trial is assessing the analgesic efficacy and safety of a new central analgesic in subjects with pain due to diabetic peripheral neuropathy (DPN).
Primary Outcome
The primary efficacy endpoint is the change from baseline in the mean of the daily average pain intensity scores (on an 11-point NRS) over the last 7 days of the 12-week maintenance (Week 16).
Interventions
- DRUG Placebo
- DRUG GRT3938Y
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 553 participants |
| Start Date | 2009-11 |
| Est. Completion | 2011-01 |
| Phase | Phase 2 |
Why NCT01056315 stopped before completion
NCT01056315 is an interventional study that assigns participants to a tested intervention. The registered 553 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (316% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01056315 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01056315 about?
NCT01056315 is a clinical study titled "A Trial in Painful Diabetic Peripheral Neuropathy With GRT3983Y". This trial is assessing the analgesic efficacy and safety of a new central analgesic in subjects with pain due to diabetic peripheral neuropathy (DPN).
What is the current status of trial NCT01056315?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 553 participants. The study started on 2009-11. Estimated completion is 2011-01.
What interventions are being tested in trial NCT01056315?
The interventions under investigation include: Placebo (DRUG), GRT3938Y (DRUG).
Who is sponsoring clinical trial NCT01056315?
This trial is sponsored by Grünenthal, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01056315's enrollment target sits among peer trials
553 60th of 2000 higher than 1,941 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05786924 · 554 participants · Phase 1
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- NCT06217809 · 552 participants · NA
EmpowHer is Prevention Curriculum for Youth Ages 10-15 Years.
- NCT07146022 · 552 participants · Phase 3
Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)
- NCT06799000 · 555 participants · Phase 3
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia